Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) — a single-center, single-blind, randomized placebo-controlled trial | Zendy

Karol Zbroński | Zendy; Kajetan Grodecki | Zendy; Roksana Gozdowska | Zendy; Ewa Ostrowska | Zendy; Julia Wysińska | Zendy; Bartosz Rymuza | Zendy; Piotr Ścisło | Zendy; Radosław Wilimski | Zendy; Janusz Kochman | Zendy; Krzysztof J. Filipiak‬ | Zendy; Grzegorz Opolski | Zendy; Ze Huczek | Zendy

Open Access

Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) — a single-center, single-blind, randomized placebo-controlled trial

Author(s) -

Karol Zbroński,

Kajetan Grodecki,

Roksana Gozdowska,

Ewa Ostrowska,

Julia Wysińska,

Bartosz Rymuza,

Piotr Ścisło,

Radosław Wilimski,

Janusz Kochman,

Krzysztof J. Filipiak‬,

Grzegorz Opolski,

Ze Huczek

Publication year - 2021

Publication title -

kardiologia polska

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.527

H-Index - 34

eISSN - 1897-4279

pISSN - 0022-9032

DOI - 10.33963/kp.a2021.0070

Subject(s) - medicine , clinical endpoint , protamine sulfate , randomized controlled trial , placebo , surgery , odds ratio , single center , population , confidence interval , heparin , anesthesia , protamine , alternative medicine , environmental health , pathology

Bleeding complications after transcatheter aortic valve implantation (TAVI) negatively affect the post-procedural prognosis. Routine use of protamine sulfate (PS) to reverse unfractionated heparin after TAVI was never assessed in a randomized controlled trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research